MERSANA THERAPEUTICS INC (MRSN) Stock Price, Forecast & Analysis
NASDAQ:MRSN • US59045L2051
MRSN Key Statistics, Chart & Performance
The current stock price of MRSN is 29.08 USD. In the past month the price increased by 5.86%. In the past year, price increased by 61.56%.
MRSN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to MRSN. When comparing the yearly performance of all stocks, MRSN is one of the better performing stocks in the market, outperforming 98.16% of all stocks.
MRSN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MRSN. MRSN has a bad profitability rating. Also its financial health evaluation is rather negative.
MRSN Financial Highlights
Over the last trailing twelve months MRSN reported a non-GAAP Earnings per Share(EPS) of -13.88. The EPS increased by 8.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -111.8% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MRSN Forecast & Estimates
14 analysts have analysed MRSN and the average price target is 51 USD. This implies a price increase of 75.38% is expected in the next year compared to the current price of 29.08.
For the next year, analysts expect an EPS growth of 39.26% and a revenue growth -24.85% for MRSN
MRSN Ownership
MRSN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.65 | 411.552B | ||
| AMGN | AMGEN INC | 16.74 | 201.047B | ||
| GILD | GILEAD SCIENCES INC | 17.13 | 192.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.09 | 121.106B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.97 | 83.892B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.86 | 43.941B | ||
| INSM | INSMED INC | N/A | 32.101B | ||
| NTRA | NATERA INC | N/A | 29.393B | ||
| BIIB | BIOGEN INC | 12.74 | 28.709B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.11 | 20.773B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MRSN
Company Profile
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2017-06-28. The firm also focuses on adult oncology. Its pipeline includes tovorafenib (OJEMDA), DAY301, emiltatug ledadotin (Emi-Le), a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC). The company has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells.
Company Info
MERSANA THERAPEUTICS INC
840 Memorial Drive
Cambridge MASSACHUSETTS 02139 US
CEO: Anna Protopapas
Employees: 102
Phone: 16174980020
MERSANA THERAPEUTICS INC / MRSN FAQ
What does MRSN do?
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2017-06-28. The firm also focuses on adult oncology. Its pipeline includes tovorafenib (OJEMDA), DAY301, emiltatug ledadotin (Emi-Le), a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC). The company has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells.
What is the current price of MRSN stock?
The current stock price of MRSN is 29.08 USD. The price increased by 0.14% in the last trading session.
Does MERSANA THERAPEUTICS INC pay dividends?
MRSN does not pay a dividend.
What is the ChartMill rating of MERSANA THERAPEUTICS INC stock?
MRSN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for MRSN stock?
14 analysts have analysed MRSN and the average price target is 51 USD. This implies a price increase of 75.38% is expected in the next year compared to the current price of 29.08.
How many employees does MERSANA THERAPEUTICS INC have?
MERSANA THERAPEUTICS INC (MRSN) currently has 102 employees.